IntrinsicIntrinsic
← All summaries

Apogee Therapeutics, Inc.

APGE
Financials & Chart →

Business Summary

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing optimized, novel biologics for inflammatory and immunology (I&I) markets, including atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), and chronic obstructive pulmonary disease (COPD) 96. The company's core business model revolves around the discovery and development of antibody programs designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties 96. Revenue generation is currently absent, with future prospects tied to successful clinical development, regulatory approval, and commercialization of its product candidates, or through collaboration and licensing agreements 97. The primary customer segments are patients suffering from I&I indications, with a focus on delivering differentiated efficacy and dosing 96.

The company's pipeline includes multiple antibody programs, both as monotherapies and combinations, based on four validated targets. Zumilokibart (APG777) is a subcutaneous extended half-life monoclonal antibody (mAb) targeting IL-13, with a Phase 1 trial in healthy volunteers showing a half-life of 77 days, supporting potential every three- to six-month maintenance dosing in AD . Positive 16-week data from Part A of the APEX Phase 2 trial in moderate-to-severe AD patients demonstrated a 71.0% Eczema Area Severity Index (EASI) reduction compared to 33.8% for placebo (p < 0.001) . APG279 is a combination of zumilokibart and APG990, a novel SQ, half-life extended mAb targeting OX40L, currently in a Phase 1b trial against DUPIXENT in AD patients . APG273 combines zumilokibart with APG333, a novel SQ, half-life extended mAb targeting thymic stromal lymphopoietin (TSLP), with a Phase 1 trial showing APG333 had a half-life of approximately 55 days . APG808 is an SQ extended half-life mAb targeting IL-4Rα, which demonstrated a half-life of approximately 55 days in a Phase 1 trial and positive interim results in mild-to-moderate asthma patients in May 2025 , .

For the fiscal year ended December 31, 2025, Apogee Therapeutics reported a net loss of $255.8 million 99. Total operating expenses were $285.6 million 99. Research and development expenses amounted to $214.7 million 100, and general and administrative expenses were $70.9 million 101. Interest income was $30.0 million 99. The company had cash and cash equivalents of $131.5 million, marketable securities of $598.6 million, and long-term marketable securities of $172.7 million as of December 31, 2025 101. The accumulated deficit as of December 31, 2025, was $561.8 million 96.

Comparing the year ended December 31, 2025, to December 31, 2024, total operating expenses increased by $68.7 million, from $216.9 million to $285.6 million 99. Research and development expenses increased by $46.8 million, from $167.9 million to $214.7 million 100. This increase was primarily driven by a $27.2 million increase in the zumilokibart program due to clinical trial and manufacturing activities, and increases in personnel-related expenses and equity-based compensation of $29.5 million and $12.4 million, respectively 100. These increases were partially offset by decreases in expenses for the APG990/APG279 program ($3.8 million decrease), APG333/APG273 program ($22.8 million decrease), and APG808 program ($7.2 million decrease) 100. General and administrative expenses increased by $21.9 million, from $49.0 million to $70.9 million, mainly due to increases in personnel-related expenses ($9.8 million) and equity-based compensation ($10.5 million) 101. Interest income decreased by $4.7 million, from $34.7 million to $30.0 million 99.

Significant operational developments during the period include the announcement of positive interim safety and PK data for zumilokibart in March 2024, showing a half-life of 77 days . In May 2024, dosing of the first patient in the APEX Phase 2 clinical trial for moderate-to-severe AD was announced, followed by positive 16-week data from Part A in July 2025 . In February 2025, dosing commenced for Part B of the APEX Phase 2 trial, which completed enrollment ahead of schedule with 347 patients in January 2026 . A Phase 1b trial of zumilokibart in mild-to-moderate asthma patients was initiated in April 2025, with positive interim data announced in January 2026 . For APG990, a Phase 1 clinical trial was initiated in August 2024, with positive interim safety and PK data (half-life of approximately 60 days) announced in March 2025 . Dosing commenced in the Phase 1b trial of APG279 against DUPIXENT in AD patients in July 2025 . A Phase 1 clinical trial of APG333 in healthy volunteers was initiated in December 2024, with positive interim safety, PK, and PD results (half-life of approximately 55 days) announced in November 2025 . For APG808, dosing of healthy volunteers began in March 2024, and asthma patients in September 2024, with positive interim safety, PK, and PD data (half-life of approximately 55 days) announced in December 2024, and positive interim results from the Phase 1b trial in mild-to-moderate asthma in May 2025 . The company also entered into a Master Services Agreement with Samsung Biologics in March 2025 for the manufacture and supply of zumilokibart drug substance for clinical development and commercial sale, if approved, and a separate PSA in February 2026 for commercial manufacture .

Business Outlook

Management anticipates reporting Part A maintenance data for zumilokibart in March 2026 . Topline induction data from Part B of the APEX Phase 2 trial is expected in the second quarter of 2026 . Subject to positive results and regulatory alignment with the U.S. Food and Drug Administration (FDA), the company plans to initiate a Phase 3 trial in AD in the second half of 2026, aiming for a potential launch of zumilokibart for AD in 2029 . Plans to further evaluate zumilokibart in the ASPIRE Phase 2 asthma trial are expected to be shared later in 2026 . The company also expects to announce plans for the Phase 2 trial in EoE in 2026 .

Major growth vectors include the expansion of zumilokibart into additional indications beyond AD, asthma, and EoE, such as alopecia areata, chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria, and prurigo nodularis, with dose selections to be determined by results from the Phase 1b asthma trial and Part B of the APEX Phase 2 AD trial in 2027 and beyond . Additionally, the company plans to evaluate zumilokibart in combination with other investigational therapies within its pipeline, such as APG279 (zumilokibart + APG990) and APG273 (zumilokibart + APG333), to potentially enable greater efficacy for I&I conditions . APG279, a potential first-in-class coformulation for AD, is currently in a Phase 1b trial against DUPIXENT, with a data readout expected in the second half of 2026 . APG273, a potential quarterly or less frequently dosed co-formulation for asthma and COPD, will have additional clinical plans announced in 2026 to support advancement into future combination trials , .

The company expects its operating expenses to increase substantially for the foreseeable future as it continues to invest in research and development activities for its programs, including clinical trials and manufacturing, and as it incurs expenses associated with being a public company 98. Personnel-related expenses and equity-based compensation are expected to increase due to increased headcount and the fair value of equity awards granted 101.

Regarding capital allocation, the company estimates that its existing cash, cash equivalents, marketable securities, and long-term marketable securities, totaling $131.5 million, $598.6 million, and $172.7 million respectively as of December 31, 2025, will be sufficient to fund operating expenses and capital expenditure requirements into the second half of 2028 103. The company has no committed external sources of funds and may need to seek additional financing through equity offerings, debt financings, or collaborations 58. During the year ended December 31, 2025, the company sold 1,175,701 shares of common stock under its ATM Facility for gross proceeds of $67.6 million, with $187.5 million remaining available for sale 102. In October 2025, the company issued and sold 8,048,782 shares of common stock and pre-funded warrants for net proceeds of $324.1 million 96.

Management has explicitly flagged several structural headwinds and execution risks. The global macroeconomic environment is uncertain, with potential negative impacts from financial market volatility, inflation, interest rate fluctuations, changing tariff policies, trade restrictions, government shutdowns, instability in the global banking system, cybersecurity events, and geopolitical conflicts 96. The company relies on foreign contract manufacturing organizations (CMOs), including WuXi Biologics and Samsung Biologics, which may be subject to U.S. legislation like the BIOSECURE Act, sanctions, trade restrictions, and other foreign regulatory requirements, potentially increasing costs, reducing supply, or delaying procurement 69. Geopolitical tensions, such as those related to Russia-Ukraine and Israel-Hamas conflicts, and rising tensions with China, could create extreme volatility in global capital markets and disrupt the global supply chain 91.

Risk Factors

The company faces material risks including its status as a clinical-stage biotechnology company with no approved products and a limited operating history, making future success and viability difficult to evaluate 57. Substantial additional capital will be required to finance future operations, and the inability to raise such capital on acceptable terms could force delays, reductions, or elimination of development programs or commercialization efforts 57. Significant losses have been incurred since inception, with net losses of $255.8 million for the year ended December 31, 2025, and an accumulated deficit of $561.8 million, and significant losses are expected to continue for the foreseeable future 59, 96. The company faces intense competition from major pharmaceutical and biotechnology companies with greater resources and expertise, which could prevent significant market penetration 60. Product candidates are in early stages of development and may fail or suffer delays in preclinical or clinical trials, which are lengthy, expensive, and have uncertain outcomes, with earlier results not being predictive of future success 61, 63. Difficulties in patient enrollment for clinical trials could delay development activities 65. Reliance on third-party collaborations and licensing arrangements, particularly with related party Paragon, carries risks of delays, non-performance, or termination, which could adversely affect the pipeline and development timeline 68. Dependence on foreign CMOs like WuXi Biologics and Samsung Biologics exposes the company to supply chain disruptions, regulatory risks, and increased costs, especially given potential impacts from U.S. legislation like the BIOSECURE Act and geopolitical tensions 69. The ability to protect patents and other proprietary rights is uncertain, with an early-stage intellectual property portfolio and only one issued patent as of January 31, 2026, exposing the company to potential loss of competitive advantage, infringement claims, and challenges to inventorship or ownership 76. The regulatory approval processes of the FDA and other foreign authorities are lengthy, unpredictable, and subject to delays, with no guarantee of approval or broad indications 82. Disruptions at government agencies, such as the FDA, due to budget issues or leadership changes, could negatively affect regulatory review and approval 83. Compliance with stringent and changing laws, regulations, and standards related to privacy, data protection, and data security, including those concerning generative AI, is critical, and failure to comply could lead to significant penalties, litigation, and reputational harm 73. Unfavorable pricing regulations and third-party coverage/reimbursement policies could prevent appropriate pricing and market access for any approved products 85.

Management Priorities

Management's overall tone emphasizes a strategic focus on advancing optimized, novel biologics to address unmet needs in large inflammatory and immunology markets, aiming for differentiated efficacy and dosing 96. They highlight the company's broad pipeline and depth of expertise as key strengths to deliver value to underserved patients 96. A core strategic priority is advancing zumilokibart (APG777) through clinical development, regulatory filings, approval, and launch for atopic dermatitis, with a potential launch targeted for 2029 . Another key priority is advancing combination therapies, specifically APG279 for dual inhibition of OX40L and IL-13, and APG273 for dual inhibition of TSLP and IL-13 . Management also prioritizes maximizing the potential of its programs through indication expansion beyond AD, including asthma, EoE, and COPD, and evaluating additional opportunities for other I&I indications . They explicitly state that existing cash, cash equivalents, and marketable securities are estimated to be sufficient to fund operating expenses and capital expenditure requirements into the second half of 2028 103.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Our Pipeline
  2. [2] Item 1, Business — Zumilokibart (APG777) – anti-IL13 antibody
  3. [3] Item 1, Business — APEX Phase 2 Trial for Patients with AD
  4. [4] Item 1, Business — Phase 1b Trial in Patients with Asthma
  5. [5] Item 1, Business — APG279 – Combination of zumilokibart (APG777) and APG990 – anti-OX40L antibody
  6. [6] Item 1, Business — APG273 – Combination of zumilokibart (APG777) and APG333 - anti-TSLP antibody
  7. [7] Item 1, Business — APG808 – anti-IL4Rα antibody
  8. [8] Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations — Net Loss
  9. [9] Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations — Comparison of the Year Ended December 31, 2025 and Year Ended December 31, 2024
  10. [10] Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations — Research and Development Expense
  11. [11] Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations — General and Administrative Expense
  12. [12] Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations — Other Income, Net
  13. [13] Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations — Sources of Liquidity
  14. [14] Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations — Future Funding Requirements
  15. [15] Item 1, Business — Our Strategy
  16. [16] Item 1, Business — Expansion Opportunities in Other Indications
  17. [17] Item 1, Business — Our Approach
  18. [18] Item 1A, Risk Factors — Risks Related to Our Limited Operating History, Financial Position and Capital Requirements
  19. [19] Item 1A, Risk Factors — Our reliance on foreign CMOs may expose us to supply chain disruption, delays in our clinical development programs, regulatory risks and increased costs, which may have a material adverse effect on our business, financial condition, results of operations and prospects.
  20. [20] Item 1A, Risk Factors — Our business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters, public health crises, political crises, geopolitical events, such as the conflict between Russia and Ukraine, and Israel and Hamas or other macroeconomic conditions, which could have a material and adverse effect on our results of operations and financial condition.
  21. [21] Item 1, Business — Patent Rights Relating to Our IL-13 Program
  22. [22] Item 1A, Risk Factors — Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage.
  23. [23] Item 1A, Risk Factors — The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable.
  24. [24] Item 1A, Risk Factors — Disruptions at the FDA and other government agencies could negatively affect the review and approval of our regulatory submissions, which could negatively impact our business.
  25. [25] Item 1A, Risk Factors — We are subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection, and data security.
  26. [26] Item 1A, Risk Factors — Even if we are able to commercialize any product candidates, due to potential unfavorable pricing regulations and/or third-party coverage/access and reimbursement policies, we may not be able to realize access to products or appropriate pricing, which would seriously harm our business.

Analysis on 5/22/2026